1. Scrip
  2. >>R&D

Biopharma Leaders Talk Radical Steps, Regulatory Reform, Open AI To Spur India R&D

 
• By Anju Ghangurde

Biopharma experts including Nobel Laureate Professor Jack Szostak share their views on emerging innovation ecosystems and how India can get it right as it seeks to shift gears in R&D. Panelists noted that VC investments can be a mixed bag, called for regulatory vision that ensures safety alongside accelerated pathways like the LPAD in the US and also ‘open” AI platforms.

L-R: Dr. Ajit Rangnekar, Dr. Harish Iyer, Dr. Yamuna Krishnan, Dr. Radha Rangarajan, Mr Satish Reddy, Professor Jack W. Szostak, Dr. Guru N. Reddy, Dr. Shridhar Narayanan, Dr. Ravindranathan, Dr. Murali Ramachandra, Dr. Srinivas Oruganti, Anju Ghangurde, Tejasvi Poorna Chandra and Dinesh Reddy Musukula. • Source: Dr Reddy's Laboratories

A high-profile biopharma panel that included Nobel Laureate Professor Jack W. Szostak recently discussed how India could invigorate its innovation ecosystem and support cutting-edge R&D. The prescription was clear: think radical, think artificial intelligence, channelize large investments, re-imagine regulatory processes and take a leaf out of the China success story.

Professor Szostak set the tone for the discussion, noting how the US had a long history of large investments by the government and by venture

Roundtable Participants

Chair: Satish Reddy, Chairman, Dr. Reddy’s Laboratories Ltd.

Panelists:

  • Professor Jack W. Szostak, Nobel Laureate

  • Dr. Harish Iyer, Deputy Director, Digital and Health Innovation – India Office, Bill & Melinda Gates Foundation

  • Dr. Yamuna Krishnan, Professor, Department of Chemistry, University of Chicago

  • Dr. Shridhar Narayanan, Indian Pharmaceutical Alliance

  • Dr. Srinivas Oruganti, Director, Dr Reddy’s Institute of Life Sciences

  • Dr. Murali Ramachandra, CEO, Aurigene Oncology

  • Dr. Radha Rangarajan, Director, CSIR-CDRI

  • Dr

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.